Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ipsen Appoints New EVP

By Drug Discovery Trends Editor | January 10, 2014

Ipsen announced the appointment of Jonathan Barnsley as executive vice president in charge of technical operations. He will be a member of the Executive Committee of the Ipsen group. He will take up his new position on April 1, reporting directly to Christel Bories, deputy CEO of the Ipsen group.
 
In line with the new organization implemented in last November, Jonathan Barnsley will be in charge of the Specialty Care production facilities and CMC (Chemistry, Manufacturing and Controls) and will have a functional link to Primary Care production facilities. Support functions to technical operations (purchasing, quality, EHS…) will also report to him.
 
English and Swiss national, Jonathan Barnsley is graduated from Sheffield University in chemical engineering. He has acquired a broad range of experience in the biotech and pharmaceutical industry on an international level and has held senior positions in manufacturing, development and engineering (notably within Beecham Pharmaceuticals Ltd., GD Searle Company Ltd., Celltech Ltd., Biocompatibles Ltd. and GSK).
 
He spent the last 18 years within Merck Serono, where he held various positions of leadership in corporate engineering and manufacturing. In 2000, he became site director of Serono Biotech Center (Vevey, CH). In 2007, he was appointed senior vice president of biotech manufacturing with the responsibility of six manufacturing sites and since 2013 senior vice president of biotech development covering the development of processes for transfer to manufacturing.
 
Date: January 10, 2014
Source: Ipsen
 

Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE